Amedica (NASDAQ: AMDA) and Second Sight Medical Products (NASDAQ:EYES) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, earnings, risk, dividends, analyst recommendations, institutional ownership and valuation.
This table compares Amedica and Second Sight Medical Products’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Second Sight Medical Products||-565.12%||-184.87%||-137.77%|
This table compares Amedica and Second Sight Medical Products’ revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Amedica||$15.23 million||0.45||-$14.76 million||N/A||N/A|
|Second Sight Medical Products||$3.98 million||24.41||-$33.17 million||($0.67)||-2.55|
Amedica has higher revenue and earnings than Second Sight Medical Products.
Institutional and Insider Ownership
61.8% of Amedica shares are held by institutional investors. Comparatively, 12.7% of Second Sight Medical Products shares are held by institutional investors. 0.1% of Amedica shares are held by company insiders. Comparatively, 34.7% of Second Sight Medical Products shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
Volatility and Risk
Amedica has a beta of -1.82, suggesting that its share price is 282% less volatile than the S&P 500. Comparatively, Second Sight Medical Products has a beta of 3.45, suggesting that its share price is 245% more volatile than the S&P 500.
This is a summary of recent ratings and recommmendations for Amedica and Second Sight Medical Products, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Second Sight Medical Products||0||0||1||0||3.00|
Amedica presently has a consensus target price of $60.00, suggesting a potential upside of 2,602.70%. Second Sight Medical Products has a consensus target price of $5.00, suggesting a potential upside of 192.40%. Given Amedica’s higher possible upside, research analysts plainly believe Amedica is more favorable than Second Sight Medical Products.
Amedica beats Second Sight Medical Products on 7 of the 12 factors compared between the two stocks.
Amedica Corporation is a commercial biomaterial company. The Company is a vertically integrated silicon nitride orthopedic medical device manufacturer. It is focused on using its silicon nitride ceramic technology platform to develop, manufacture and sell a range of medical devices. It is also engaged in developing wear- and corrosion-resistant implant components for hip and knee arthroplasty. The Company markets its Valeo family of silicon nitride interbody spinal fusion devices in the United States, Europe and Brazil for use in the cervical and thoracolumbar areas of the spine. In addition to its silicon nitride-based spinal fusion products, it markets a line of non-silicon nitride spinal surgery products, which allows the Company to provide surgeons and hospitals with a solution for spinal procedures. Its Valeo interbody spinal fusion devices include Anterior Lumbar, Posterior Lumbar, Oblique Lumbar, Transforaminal Lumbar, Lateral Lumbar, Cervical and Corpectomy.
About Second Sight Medical Products
Second Sight Medical Products, Inc. is engaged in developing, manufacturing and marketing prosthetic devices that restore vision to blind individuals. The Company’s product, the Argus II System, treats outer retinal degenerations, such as retinitis pigmentosa (RP). The Argus II System provides an artificial form of vision that differs from the vision of people with normal sight. It does not restore normal vision and it does not slow or reverse the progression of the disease. The Company’s Argus II System employs electrical stimulation to bypass degenerated photoreceptor cells and to stimulate remaining viable retinal cells thereby inducing visual perception in blind individuals. The Argus II System works by converting video images captured by a miniature camera housed in a patient’s glasses into a series of small electrical pulses that are transmitted wirelessly to an array of electrodes that are implanted on the surface of the retina.
Receive News & Ratings for Amedica Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amedica and related companies with MarketBeat.com's FREE daily email newsletter.